Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Revenue data on file, last reported at $136.0 million in Q1 2026.

• Revenue for Q1 2026 came in at $136.0 million, down 2.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $669.7 million (up 13.48% YoY), and the FY2025 annual result was $673.0 million, up 20.18% from the prior year.
• Revenue declined to $136.0 million in Q1 2026 per RARE's latest filing, from $207.3 million in the prior quarter.
• Over five years, Revenue peaked at $207.3 million in Q4 2025 and troughed at $79.9 million in Q1 2022.
• A 5-year average of $127.4 million and a median of $127.1 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue declined 19.58% in 2022, then jumped 42.27% in 2024.
• A 5-year view of Revenue shows it stood at $103.3 million in 2022, then advanced by 23.02% to $127.1 million in 2023, then gained by 29.5% to $164.6 million in 2024, then increased by 25.89% to $207.3 million in 2025, then plunged by 34.39% to $136.0 million in 2026.
• Business Quant data shows RARE's Revenue at $136.0 million in Q1 2026, $207.3 million in Q4 2025, and $159.9 million in Q3 2025.